Komori
Other Disclosures4599StemRIM Inc.Pharmaceuticals

Notice of the registration in Israel of a patent covering regenerative medicine drug redasemtide (HMGB1 fragment peptide) for cartilage disorders

An indication patent for a treatment for cartilage disorders using redasemtide will be registered in Israel. The registration number has not yet been assigned.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Regenerative medicine Redasemtide (HMGB1 fragment peptide)S-005151
Applicable field (uses covered by this announcement)
Traumatic cartilage defectsOsteoarthritisOsteochondritis dissecans and other conditions
Relationship between the counterparty and the company
StemRIM Inc.4599
Relationship with the Company

Redasemtide has already been out-licensed to Shionogi & Co.,Ltd. The patent applicants are StemRIM Inc. and Osaka University.

CounterpartyShionogi & Co.,Ltd.

Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功); business activities, capital and year established: Not disclosed

Registration number and expiry date

Application number: 282377; registration (publication) number: not yet determined; validity period: Not disclosed

Impact on Business Performance

There will be no impact on full-year results for the fiscal year ending July 2027. The Company will promptly disclose any matters requiring disclosure that arise.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredRegenerative medicine Redasemtide (HMGB1 fragment peptide), S-005151
CounterpartyShionogi & Co.,Ltd.
Counterparty overviewHead office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功); business activities, capital and year established: Not disclosed
Relationship with the CompanyRedasemtide has already been out-licensed to Shionogi & Co.,Ltd. The patent applicants are StemRIM Inc. and Osaka University.
Applicable areaTraumatic cartilage defects, Osteoarthritis, Osteochondritis dissecans and other conditions
Registration number and expiry dateApplication number: 282377; registration (publication) number: not yet determined; validity period: Not disclosed
Impact on Business PerformanceThere will be no impact on full-year results for the fiscal year ending July 2027. The Company will promptly disclose any matters requiring disclosure that arise.
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand the indications for redasemtide and secure the possibility of developing a treatment for cartilage disorders in Israel.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the registration in Israel of a patent covering regenerative medicine drug redasemtide (HMGB1 fragment peptide) for cartilage disorders | StemRIM Inc. (4599) timely disclosure | Komori